FDA Panel: Cardiac Surgery Adhesion Barrier Use Should Be Limited To Kids
This article was originally published in The Gray Sheet
Executive Summary
SyntheMed's Repel-CV cardiac surgery adhesion barrier should be approved only for pediatric patients since pivotal trial data on newborns cannot be extrapolated to the adult population, FDA's Circulatory System Devices advisory panel recommended Sept. 19
You may also be interested in...
Wariness Of Cardiovascular Adhesion Barrier Trials At FDA Panel
Panelists advising FDA officials on how to design clinical trials for cardiovascular adhesion barriers said that until they better understand the benefits of these devices, they are reluctant to expose heart patients to more than the slightest of risks
Wariness Of Cardiovascular Adhesion Barrier Trials At FDA Panel
Panelists advising FDA officials on how to design clinical trials for cardiovascular adhesion barriers said that until they better understand the benefits of these devices, they are reluctant to expose heart patients to more than the slightest of risks
SyntheMed Assembles Sales Force For Repel-CV Cardiac Adhesion Barrier
SyntheMed will launch its newly approved Repel-CV cardiac surgery adhesion barrier in the United States through two or three direct sales reps and a "much more significant" force of independent distributors, according to CEO Robert P. Hickey